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Background: Patients treated with renal failure have been reported having high incidence of mortality and other complications rate after PCI. 
Optimal treatment of PCI for renal failure patients with dialysis is still unknown. Aim: The aim of this study is to compare the safety and efficacy of 
Sirolimus (SES), Paclitaxel (PES), EPC capture (ECS), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES) and Everolimus-eluting stent (EES) 
on the outcome of percutaneous coronary intervention in renal failure patients with dialysis (CRF-HD). 
Methods: A prospective analysis of 1013 patients with CRF-HD (258 SES, 244 PES, 77 ECS, 118 ZES-R, 128 BES, 188 EES) in six high volume Asian 
centers after successful stenting was performed. The study endpoints were 30 days major adverse cardiac events (MACE) and 12, 24 and 36 months 
target lesion revascularization (TLR) and MACE. 
Results: The baseline clinical characteristics between 5 groups were similar. See table for clinical result. 
Conclusion: The use of drug-eluting stents in patient with CRF-HD was safe with low acute complication. Patients treated with PES and EES showed 
lesser incidence of restenosis rate and TLR compared with other drug-eluting stents. 
SES PES ECS ZES-R BES EES
Number of patients 258 244 77 118 128 188
Multivessel disease (%) 89.1 87.7 85.7 83.4 79.6 89.3
MACE at 30 days (%) 0.8 1.2 1.3 0.8 0.8 0.5
Reference diameter (mean: mm) 2.80 2.79 2.88 2.85 2.86 2.91
Lesion type: % of B2, C (%) 64.0 67.7 56.6 63.7 67.1 61.9
Stent length (mean: mm) 28.9 29.5 26.2 26.9 29.9 27.8
MLD at baseline (mean: mm) 2.65 2.63 2.68 2.59 2.60 2.66
12 months TLR (%) 15.1 9.8* 20.8 16.9 18.8 9.5*
MACE (%) 19.4 12.7* 23.4 19.5 20.3 12.2*
24 months TLR (%) 17.8 11.9* 23.4 19.5 20.3 13.8*
MACE (%) 22.4 14.8* 26.0 22.9 22.6 17.0*
36 months TLR (%) 19.4 12.7* 26.0 21.2 21.9 17.0*
MACE (%) 25.2 16.8* 29.9 25.4 25.0 20.2*
*p<0.05 vs. SES, ECS, ZES-R and BES.
